Arkadios Wealth Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Arkadios Wealth Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.1K	Hold	20,000	–	–	﹤0.01%	1749
2026 Q1	$18K	Hold	20,000	–	–	﹤0.01%	1673
2025 Q4	$15.5K	Hold	20,000	–	–	﹤0.01%	1551
2025 Q3	$24.8K	Hold	20,000	–	–	﹤0.01%	1453
2025 Q2	$31.8K	Buy	20,000 +10,000	+100%	+$9.16K	﹤0.01%	1299
2025 Q1	$14.9K	Hold	10,000	–	–	﹤0.01%	1117
2024 Q4	$40K	Buy	10,000 +2,000	+25%	+$13.5K	﹤0.01%	908
2024 Q3	$100K	Buy	8,000 +2,000	+33%	+$33.7K	0.01%	876
2024 Q2	$87.6K	Buy	6,000 +2,000	+50%	+$35.8K	0.01%	803
2024 Q1	$89.7K	Hold	4,000	–	–	0.01%	678
2023 Q4	$75.7K	Hold	4,000	–	–	0.01%	679
2023 Q3	$68.4K	Buy	+4,000	New	+$95.1K	0.01%	652

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MFS

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

Arkadios Wealth Advisors's CTXR Position: Q2 2026 in Review

Arkadios Wealth Advisors held its Citius Pharmaceuticals (CTXR) position steady in Q2 2026 at 20,000 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1749.

Arkadios Wealth Advisors first reported a position in CTXR in Q3 2023 and has held it in 12 quarters since. The position peaked at $100K in Q3 2024. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

Arkadios Wealth Advisors held 20,000 shares of Citius Pharmaceuticals worth $12.1K as of Q2 2026.
Arkadios Wealth Advisors left its Citius Pharmaceuticals share count unchanged in Q2 2026.
Citius Pharmaceuticals made up ﹤0.01% of Arkadios Wealth Advisors's portfolio in Q2 2026, its #1749 holding.
Arkadios Wealth Advisors first reported a position in Citius Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Arkadios Wealth Advisors's Citius Pharmaceuticals position peaked at $100K in Q3 2024.
43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.